[EN] SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS<br/>[FR] RÉACTIFS DE MÉTHYLFORMYLE SUBSTITUÉ ET PROCÉDÉ D'UTILISATION DE CEUX-CI POUR MODIFIER DES PROPRIÉTÉS PHYSICOCHIMIQUES ET/OU PHARMACOCINÉTIQUES DE COMPOSÉS
申请人:SPHAERA PHARMA PRIVATE LTD
公开号:WO2012137225A1
公开(公告)日:2012-10-11
The present invention relates to the synthesis and application of novel chiral/ achiral substituted methyl formyl reagents to modify pharmaceutical agents and/or biologically active substances to modify the physicochemical, biological and/or pharmacokinetic properties of the resulting compounds from the unmodified original agent.
Novel compounds and their synthesis are described. Methods for using these compounds in the prevention or treatment of cancer, a bacterial infection or a viral infection in a subject are also described.
[EN] COMPOSITIONS AND METHODS FOR INHIBITING KINASES<br/>[FR] COMPOSITIONS ET MÉTHODES POUR INHIBER LES KINASES
申请人:INHIBIKASE THERAPEUTICS INC
公开号:WO2018081251A1
公开(公告)日:2018-05-03
The present invention provides methods for the prevention or treatment of Parkinson's Disease using Abelson-family tyrosine kinase inhibitors.
本发明提供了使用阿贝尔森家族酪氨酸激酶抑制剂预防或治疗帕金森病的方法。
Antiviral Compounds
申请人:Chaudhary Kleem
公开号:US20080311077A1
公开(公告)日:2008-12-18
The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS
申请人:Dugar Sundeep
公开号:US20140121367A1
公开(公告)日:2014-05-01
The present invention relates to the synthesis and application of novel chiral/achiral substituted methyl formyl reagents to modify pharmaceutical agents and/or biologically active substances to modify the physicochemical, biological and/or pharmacokinetic properties of the resulting compounds from the unmodified original agent.